In early June, Honeybear Biosciences CEO Dr. Shih-Hsien Chuang led a group to South Korea to attend the World ADC Asia conference. Invited as both session chair and speaker, Dr. Chuang shared insights on how the proprietary CoNectar® technology platform unlocks new possibilities in ADC drug development. He also presented the latest research progress on ARC (Antibody Radionuclide Conjugate), which sparked enthusiastic discussion and strong interest from attendees. The presentation not only received an overwhelming response but also brought international attention to Taiwan’s R&D capabilities.
